메뉴 건너뛰기




Volumn 31, Issue 5, 2017, Pages 1108-1116

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

(31)  Ilander, M a   Olsson Stromberg U b,c   Schlums, H d   Guilhot, J e   Bruck O a   Lahteenmaki H a   Kasanen, T a   Koskenvesa, P a   Soderlund S b   Hoglund M b   Markevarn B f   Sjalander A g   Lotfi, K h   Dreimane, A h   Lubking A i   Holm, E i   Bjoreman M j   Lehmann, S b,c,d   Stenke, L d   Ohm, L d   more..


Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; DASATINIB; FC RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMATINIB; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL KILLER CELL RECEPTOR; NILOTINIB; RANTES; TUMOR NECROSIS FACTOR; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; CYTOKINE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

EID: 85006312419     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.360     Document Type: Article
Times cited : (197)

References (42)
  • 1
    • 67349233062 scopus 로고    scopus 로고
    • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    • Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
    • (2009) Leukemia , vol.23 , pp. 1054-1061
    • Hochhaus, A.1    O'Brien, S.G.2    Guilhot, F.3    Druker, B.J.4    Branford, S.5    Foroni, L.6
  • 2
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3    Cortes, J.4    Shah, S.5    Ayala, M.6
  • 5
    • 0038454621 scopus 로고    scopus 로고
    • Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
    • Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.
    • (2003) Blood , vol.101 , pp. 4701-4707
    • Bhatia, R.1    Holtz, M.2    Niu, N.3    Gray, R.4    Snyder, D.S.5    Sawyers, C.L.6
  • 6
    • 84973137731 scopus 로고    scopus 로고
    • European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
    • Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648-1671.
    • (2016) Leukemia , vol.30 , pp. 1648-1671
    • Steegmann, J.L.1    Baccarani, M.2    Breccia, M.3    Casado, L.F.4    Garcia-Gutierrez, V.5    Hochhaus, A.6
  • 7
    • 79959311524 scopus 로고    scopus 로고
    • Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008
    • Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514-2520.
    • (2011) J Clin Oncol , vol.29 , pp. 2514-2520
    • Bjorkholm, M.1    Ohm, L.2    Eloranta, S.3    Derolf, A.4    Hultcrantz, M.5    Sjoberg, J.6
  • 8
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (STIM) trial
    • Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
    • (2010) Lancet Oncol , vol.11 , pp. 1029-1035
    • Mahon, F.X.1    Rea, D.2    Guilhot, J.3    Guilhot, F.4    Huguet, F.5    Nicolini, F.6
  • 9
    • 84886917643 scopus 로고    scopus 로고
    • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study
    • Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515-522.
    • (2013) Blood , vol.122 , pp. 515-522
    • Ross, D.M.1    Branford, S.2    Seymour, J.F.3    Schwarer, A.P.4    Arthur, C.5    Yeung, D.T.6
  • 10
    • 85010049735 scopus 로고    scopus 로고
    • Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia
    • e-pub ahead of print 31 October 2016
    • Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 2016; e-pub ahead of print 31 October 2016; doi:10.1200/JCO.2016.68.2914.
    • (2016) J Clin Oncol
    • Etienne, G.1    Guilhot, J.2    Rea, D.3    Rigal-Huguet, F.4    Nicolini, F.5    Charbonnier, A.6
  • 11
    • 84960941451 scopus 로고    scopus 로고
    • Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): A multicentre phase 2 trial
    • Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015; 2: e528-e535.
    • (2015) Lancet Haematol , vol.2 , pp. e528-e535
    • Imagawa, J.1    Tanaka, H.2    Okada, M.3    Nakamae, H.4    Hino, M.5    Murai, K.6
  • 12
    • 16244366026 scopus 로고
    • Index for rating diagnostic tests
    • Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-35.
    • (1950) Cancer , vol.3 , pp. 32-35
    • Youden, W.J.1
  • 13
    • 77956634317 scopus 로고    scopus 로고
    • The BCR/ABLinhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
    • Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR et al. The BCR/ABLinhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119-2128.
    • (2010) Int J Cancer , vol.127 , pp. 2119-2128
    • Salih, J.1    Hilpert, J.2    Placke, T.3    Grunebach, F.4    Steinle, A.5    Salih, H.R.6
  • 14
    • 38949210227 scopus 로고    scopus 로고
    • Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
    • Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.
    • (2008) Blood , vol.111 , pp. 1366-1377
    • Schade, A.E.1    Schieven, G.L.2    Townsend, R.3    Jankowska, A.M.4    Susulic, V.5    Zhang, R.6
  • 15
    • 15244351682 scopus 로고    scopus 로고
    • Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner
    • Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dosedependent manner. Blood 2005; 105: 2473-2479.
    • (2005) Blood , vol.105 , pp. 2473-2479
    • Seggewiss, R.1    Lore, K.2    Greiner, E.3    Magnusson, M.K.4    Price, D.A.5    Douek, D.C.6
  • 16
    • 33846023983 scopus 로고    scopus 로고
    • Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
    • Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.
    • (2007) Blood , vol.109 , pp. 58-60
    • Rousselot, P.1    Huguet, F.2    Rea, D.3    Legros, L.4    Cayuela, J.M.5    Maarek, O.6
  • 17
    • 33646877669 scopus 로고    scopus 로고
    • Human natural killer cell development and biology
    • Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006; 20: 123-137.
    • (2006) Blood Rev , vol.20 , pp. 123-137
    • Farag, S.S.1    Caligiuri, M.A.2
  • 20
    • 84924984567 scopus 로고    scopus 로고
    • Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function
    • Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015; 42: 443-456.
    • (2015) Immunity , vol.42 , pp. 443-456
    • Schlums, H.1    Cichocki, F.2    Tesi, B.3    Theorell, J.4    Beziat, V.5    Holmes, T.D.6
  • 21
    • 84924955835 scopus 로고    scopus 로고
    • Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals
    • Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 2015; 42: 431-442.
    • (2015) Immunity , vol.42 , pp. 431-442
    • Lee, J.1    Zhang, T.2    Hwang, I.3    Kim, A.4    Nitschke, L.5    Kim, M.6
  • 22
    • 33846467149 scopus 로고    scopus 로고
    • CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
    • Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21: 356-359.
    • (2007) Leukemia , vol.21 , pp. 356-359
    • Grzywacz, B.1    Kataria, N.2    Verneris, M.R.3
  • 23
    • 10144247247 scopus 로고    scopus 로고
    • Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism
    • Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579-584.
    • (1996) J Exp Med , vol.184 , pp. 579-584
    • Zheng, L.M.1    Ojcius, D.M.2    Garaud, F.3    Roth, C.4    Maxwell, E.5    Li, Z.6
  • 24
    • 84896702820 scopus 로고    scopus 로고
    • Moving towards patient-centered decisionmaking in chronic myeloid leukemia: Assessment of quality of life and symptom burden
    • Baccarani M, Efficace F, Rosti G. Moving towards patient-centered decisionmaking in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica 2014; 99: 205-208.
    • (2014) Haematologica , vol.99 , pp. 205-208
    • Baccarani, M.1    Efficace, F.2    Rosti, G.3
  • 25
    • 84977624843 scopus 로고    scopus 로고
    • Moving treatment-free remission into mainstream clinical practice in CML
    • Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016; 128: 17-23.
    • (2016) Blood , vol.128 , pp. 17-23
    • Hughes, T.P.1    Ross, D.M.2
  • 26
    • 84973176467 scopus 로고    scopus 로고
    • The concept of treatment-free remission in chronic myeloid leukemia
    • Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 2016; 30: 1638-1647.
    • (2016) Leukemia , vol.30 , pp. 1638-1647
    • Saussele, S.1    Richter, J.2    Hochhaus, A.3    Mahon, F.X.4
  • 27
    • 0022616253 scopus 로고
    • Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
    • Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.
    • (1986) Nature , vol.319 , pp. 675-678
    • Karre, K.1    Ljunggren, H.G.2    Piontek, G.3    Kiessling, R.4
  • 28
    • 0035855872 scopus 로고    scopus 로고
    • Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
    • Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171.
    • (2001) Nature , vol.413 , pp. 165-171
    • Diefenbach, A.1    Jensen, E.R.2    Jamieson, A.M.3    Raulet, D.H.4
  • 29
    • 0035949563 scopus 로고    scopus 로고
    • Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
    • Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526.
    • (2001) Proc Natl Acad Sci USA , vol.98 , pp. 11521-11526
    • Cerwenka, A.1    Baron, J.L.2    Lanier, L.L.3
  • 30
    • 84857996055 scopus 로고    scopus 로고
    • NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice
    • Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 2012; 26: 465-474.
    • (2012) Leukemia , vol.26 , pp. 465-474
    • Chen, C.I.1    Koschmieder, S.2    Kerstiens, L.3    Schemionek, M.4    Altvater, B.5    Pscherer, S.6
  • 31
    • 84900418447 scopus 로고    scopus 로고
    • Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy
    • Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K et al. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS ONE 2014; 9: e87794.
    • (2014) PLoS ONE , vol.9 , pp. e87794
    • Ilander, M.1    Kreutzman, A.2    Rohon, P.3    Melo, T.4    Faber, E.5    Porkka, K.6
  • 32
    • 79961240453 scopus 로고    scopus 로고
    • Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile
    • Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE 2011; 6: e23022.
    • (2011) PLoS ONE , vol.6 , pp. e23022
    • Kreutzman, A.1    Rohon, P.2    Faber, E.3    Indrak, K.4    Juvonen, V.5    Kairisto, V.6
  • 33
    • 84879703012 scopus 로고    scopus 로고
    • NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
    • Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121: 3599-3608.
    • (2013) Blood , vol.121 , pp. 3599-3608
    • Romee, R.1    Foley, B.2    Lenvik, T.3    Wang, Y.4    Zhang, B.5    Ankarlo, D.6
  • 36
    • 0036569402 scopus 로고    scopus 로고
    • A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo
    • Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ. A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 2002; 168: 4472-4479.
    • (2002) J Immunol , vol.168 , pp. 4472-4479
    • Kelly, J.M.1    Takeda, K.2    Darcy, P.K.3    Yagita, H.4    Smyth, M.J.5
  • 37
    • 84863338121 scopus 로고    scopus 로고
    • Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
    • Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119: 2665-2674.
    • (2012) Blood , vol.119 , pp. 2665-2674
    • Foley, B.1    Cooley, S.2    Verneris, M.R.3    Pitt, M.4    Curtsinger, J.5    Luo, X.6
  • 38
    • 59049094662 scopus 로고    scopus 로고
    • Adaptive immune features of natural killer cells
    • Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457: 557-561.
    • (2009) Nature , vol.457 , pp. 557-561
    • Sun, J.C.1    Beilke, J.N.2    Lanier, L.L.3
  • 39
    • 79951695881 scopus 로고    scopus 로고
    • Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection
    • Sun JC, Beilke JN, Bezman NA, Lanier LL. Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med 2011; 208: 357-368.
    • (2011) J Exp Med , vol.208 , pp. 357-368
    • Sun, J.C.1    Beilke, J.N.2    Bezman, N.A.3    Lanier, L.L.4
  • 40
    • 80052602721 scopus 로고    scopus 로고
    • Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
    • Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011; 108: 14725-14732.
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 14725-14732
    • Lopez-Verges, S.1    Milush, J.M.2    Schwartz, B.S.3    Pando, M.J.4    Jarjoura, J.5    York, V.A.6
  • 42
    • 84869856060 scopus 로고    scopus 로고
    • A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
    • Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317-4323.
    • (2012) Blood , vol.120 , pp. 4317-4323
    • Vey, N.1    Bourhis, J.H.2    Boissel, N.3    Bordessoule, D.4    Prebet, T.5    Charbonnier, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.